The Efficacy of Topical 0.03% Tacrolimus Dermatologic Ointment in Treatment of Vernal Keratoconjunctivitis
Abstract
Objective: To determine the efficacy of 0.03% Tacrolimus dermatologic ointment in the treatment of Vernal
keratoconjunctivitis.
Study Design: Cross-sectional.
Place and Duration of Study: The study was conducted at Eye Donors Association Hospital, Wah Cantonment
from August 2019 to January 2020.
Materials and Methods: 103 diagnosed patients ofvernal keratoconjunctivitis, aged 3-16 years, were included
in this study. They were treated with 0.03% Tacrolimus dermatologic ointment,applied in the inferior fornix
once at night time, for a period of two months. In addition, these patients were also prescribeda topical antihistamine
(0.05 % ketotifen eye drops 3 times a day)and preservative free artificial tearsfor symptomatic relief.
The patients were evaluated at 4 and 8 weeks after the initiation of treatment. At each follow up the clinical
signs were assessed on a slit lamp biomicroscope by a single observer and recorded on a standardized grading
sheet.
Results: Out of 103 patients, 66% were male and mean age was 9 years (range 3-16 years). The mean baseline
scores showed a statistically significant decrease, with the exception of palpebral follicles & limbal Trantas dots
after 8 weeks of treatment.
Conclusion: 0.03% Tacrolimus dermatologic ointment was found to be safe and effective in the treatment of
vernal kerato-conjunctivitis.
References
Tabbara AK, El-Asrar A. Immunopathogenesis of ocular allergy. Progress in allergy and clinical immunology. Seattle: Hogrefe & Huber. 1997. p. 381–5.
Fiorentini SF, Khurram D. Therapeutic effects of topical 0.03% Tacrolimus ointment in children with refractory
vernal keratoconjunctivitis in Middle East. Saudi J Ophthalmol. 2019; 33: 117-20.
Sacchetti M, Lambiase A, Moretti C, Mantelli F, Bonini S. Sex hormones in allergic conjunctivitis: altered levels of circulating androgens and estrogens in children and adolescents with vernal keratoconjunctivitis. J Immunol
Res. 2015; 2015: 945317
Leonardi A. Vernal keratoconjunctivitis: pathogenesis and treatment. ProgRetin Eye Res. 2002; 21: 319-39.
Bonini S, Bonini S, Lambiase A, Marchi S, Pasqualetti P, Zuccaro O, et al. Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term follow up. Ophthalmology. 2000; 107: 1157-63.
Joseph MA, Kaufman HE, Insler M. Topical tacrolimus ointment for treatment of refractory anterior segment
inflammatory disorders. Cornea. 2005; 24: 417-20.
Ohashi Y, Ebihara N, Fujishima H, Fukushima A, Kumagai N, Nakagawa Y, et al. A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis. J OculPharmacolTher. 2010; 26: 165-74.
Chatterjee S, Agrawal D. Tacrolimus in Corticosteroid-Refractory Vernal Keratoconjunctivitis. Cornea. 2016; 35:
-8.
Zhai J, Gu J, Yuan J, Chen J. Tacrolimus in the treatment of ocular diseases. BioDrugs. 2011; 25: 89-103.
Sengoku T, Sakuma S, Satoh S, Kishi S, Ogawa T, Ohkubo Y, et al. Effect of FK506 eye drops on late and delayed-type responses in ocular allergy models. ClinExp Allergy. 2003; 33: 1555-60.
Yücel OE, Ulus ND. Efficacy and safety of topical cyclosporine A 0.05% in vernal keratoconjunctivitis.
Singapore Med J. 2016; 57: 507-10.
Daniell M, Constantinou M, Vu HT, Taylor HR. Randomised controlled trial of topical ciclosporin A in steroid dependent allergic conjunctivitis. Br J Ophthalmol. 2006; 90: 461-4.
Miyazaki D, Tominaga T, Kakimaru-Hasegawa A, Nagata Y, Hasegawa J, Inoue Y. Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases. Ophthalmology. 2008;115: 988-92.
Kymionis GD, Goldman D, Ide T, Yoo SH. Tacrolimus ointment 0.03% in the eye for treatment of giant papillary
conjunctivitis. Cornea. 2008; 27: 228-9.
Pacharn P Visitsunthorn N, Jirapongsananuru kO, Vichyanond, P. Vernal Keratoconjunctivitis (vkc) Treated
with 0.1% Fk-506 Ophthalmic Ointment: Result of A Three Years Follow-up. J allergclinimmunol. 2007; 119: 536-7.
Tam PM, Young AL, Cheng LL, Lam PT. Topical tacrolimus 0.03% monotherapy for vernal keratoconjunctivitis--case series. Br J Ophthalmol. 2010; 94: 1405-6.
